127 related articles for article (PubMed ID: 579186)
1. Factors influencing comparative bioavailability of spironolactone tablets.
Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
Tidd MJ; Collins WT; Chamberlain J
J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
[TBL] [Abstract][Full Text] [Related]
3. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone. II. Bioavailability.
Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo availability of spironolactone from oral dosage forms.
Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
[TBL] [Abstract][Full Text] [Related]
6. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
[TBL] [Abstract][Full Text] [Related]
7. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
Bartle WR; Coates PE; Fisher MM; Louman FJ
Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
[TBL] [Abstract][Full Text] [Related]
8. The bioavailability of two new preparations of spironolactone tablets.
Nijkerk AJ; Vermeer JM; Imanse M; De Vos D
Pharm Weekbl Sci; 1983 Oct; 5(5):210-2. PubMed ID: 6646986
[TBL] [Abstract][Full Text] [Related]
9. Enhancement by food of canrenone bioavailability from spironolactone.
Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
[TBL] [Abstract][Full Text] [Related]
10. Improved bioavailability from a spironolactone beta-cyclodextrin complex.
Yusuff NT; York P; Chrystyn H; Bramley PN; Swallow RD; Tuladhar BR; Losowsky MS
Eur J Clin Pharmacol; 1991; 40(5):507-11. PubMed ID: 1884726
[TBL] [Abstract][Full Text] [Related]
11. Canrenone--the principal active metabolite of spironolactone?
Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers.
Xu FG; Zhang ZJ; Dong HJ; Tian Y; Liu Y; Chen Y
Arzneimittelforschung; 2008; 58(3):117-21. PubMed ID: 18488807
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
Rosenthal J; Jaeger H; Specker M
Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
[TBL] [Abstract][Full Text] [Related]
14. [Bioavailability studies of two spironolactone-preparations (author's transl)].
Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
[TBL] [Abstract][Full Text] [Related]
15. [Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms].
Lucchelli PD; Monarca A; Del Mastro S; Sega R
Boll Chim Farm; 1978 Aug; 117(8):487-95. PubMed ID: 743391
[No Abstract] [Full Text] [Related]
16. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
17. The bioavailability of spironolactone hydrochlorothiazide combination preparation.
Rameis H; Hitzenberger G; Horwatitsch H
Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):327-33. PubMed ID: 7107086
[TBL] [Abstract][Full Text] [Related]
18. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.
Langguth P; Hanafy A; Frenzel D; Grenier P; Nhamias A; Ohlig T; Vergnault G; Spahn-Langguth H
Drug Dev Ind Pharm; 2005 Mar; 31(3):319-29. PubMed ID: 15830727
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
[TBL] [Abstract][Full Text] [Related]
20. Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats.
Kaukonen AM; Lennernäs H; Mannermaa JP
J Pharm Pharmacol; 1998 Jun; 50(6):611-9. PubMed ID: 9680070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
